Rapid depletion of B lymphocytes by ultra-low-dose rituximab delivered intrathecally

OBJECTIVE: We are conducting an open-label phase 1b study on the efficacy of intrathecal (IT) administration of rituximab, provided via an Ommaya reservoir, for the treatment of progressive multiple sclerosis (PMS). The objective of this initial study was to monitor B lymphocytes in peripheral blood...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Neurol Neuroimmunol Neuroinflamm
Autori principali: Svenningsson, Anders, Bergman, Joakim, Dring, Ann, Vågberg, Mattias, Birgander, Richard, Lindqvist, Thomas, Gilthorpe, Jonathan, Bergenheim, Tommy
Natura: Artigo
Lingua:Inglês
Pubblicazione: Lippincott Williams & Wilkins 2015
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4345631/
https://ncbi.nlm.nih.gov/pubmed/25745637
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/NXI.0000000000000079
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi